Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2025
0mins
Source: Globenewswire
Patent Expansion: Orchestra BioMed has secured ten new patents for hypertension treatment, increasing its total to 120 globally, and has also added 17 patents for heart failure treatment, enhancing its intellectual property portfolio significantly.
FDA Breakthrough Designation: The FDA granted Breakthrough Device Designation to Orchestra BioMed's AVIM therapy for treating uncontrolled hypertension in patients at increased cardiovascular risk, indicating the therapy's potential impact on managing severe cardiovascular conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
